文献速递肝病炎症性肠病

原发性硬化性胆管炎患者通过在线登记报告的特征与结局

Characteristics and Outcomes Reported by Patients With Primary Sclerosing Cholangitis Through an Online Registry.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-04-26

该研究分析全球PSC Partners患者登记库中873名注册者的在线问卷数据,811人完成问卷,528人确诊PSC。患者平均确诊年龄32.4±14.7岁,女性占52.5%,合并IBD者占67.1%,中位无移植生存期为21年,女性及合并克罗恩病与无移植生存相关。

要点

  • 全球在线登记库中528例确诊PSC患者,女性占52.5%,确诊平均年龄32.4±14.7岁。
  • 合并IBD者占67.1%,超过半数报告瘙痒、腹痛、疲劳或睡眠障碍。
  • 中位无移植生存期21年,女性及合并克罗恩病与无移植生存相关。

核心结论

  • PSC Partners患者登记库分析结果与既往研究一致,但本研究发现女性PSC患者比例更高。
  • 患者驱动的登记库可高效收集患者报告结局,并纳入既往代表性不足的PSC病例。

研究设计与样本

  • 分析全球PSC Partners患者登记库(2014年建立的国际在线数据库)中PSC患者的人口学与临床特征、症状及临床结局。
  • 873名注册者中811人(92.9%)完成问卷,528人(65.1%)确诊PSC;确诊与未确诊患者间无显著人口学或临床差异。

主要发现

  • 女性占52.5%,平均确诊年龄32.4±14.7岁,合并IBD者占67.1%,数据库病例多数来自美国(74.9%)。
  • 超过半数参与者报告瘙痒、腹痛、疲劳或睡眠障碍,美国内外参与者间这些症状率无显著差异。
  • 美国内外参与者熊去氧胆酸治疗率分别为50.0%和57.8%(P = .07),无显著差异。
  • 中位无移植生存期为21年,无移植生存与女性及克罗恩病相关。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is a fibrostenosing disease of the bile ducts associated with inflammatory bowel disease (IBD), for which the only treatment is liver transplantation. PSC progression has been defined in cohorts from referral centers or single-nation population databases. However, observations made from these cohorts have limited applicability owing to referral bias and demographic confounders. We analyzed data from the worldwide PSC Partners Patient Registry, an international online database established in 2014 to obtain information from individuals with PSC or their caretakers and compare symptoms, disease progression, and treatments of PSC in the United States and other countries. METHODS: We analyzed demographic and clinical characteristics, symptoms, and clinical outcomes of patients with PSC using the PSC Partners Patient Registry. Participants completed an online standardized questionnaire and electronic case report, providing information on age, age at symptom onset, age at PSC diagnosis, methods of diagnosis, concurrent diagnoses, family history, and medication use. RESULTS: Of 873 registrants, 811 (92.9%) had completed questionnaires and 528 (65.1%) had their PSC diagnosis confirmed; we found no significant demographic or clinical differences between patients with vs without a confirmed diagnosis. In contrast to other studies, we found a higher proportion of individuals with PSC to be female (52.5%). However, the mean age at PSC diagnosis (32.4 ± 14.7 y) and the proportion of individuals with PSC and IBD (67.1%) were similar to those from prior reports. Most cases in the database were from the United States (74.9%). More than half of the participants reported having pruritus, abdominal pain, fatigue, or sleep disturbances; rates were not significantly different among participants within vs outside the United States. There was no significant difference in treatment with ursodeoxycholic acid between participants within vs outside the United States (50.0% and 57.8%; P = .07). The median time of transplant-free survival was 21 years; transplant-free survival was associated with female sex and Crohn's disease. CONCLUSIONS: Our findings from an analysis of data from the PSC Partners Patient Registry confirm those from previous studies, although we found a higher proportion of individuals with PSC to be female. In addition to allowing efficient collection of patient-reported outcomes, the patient-driven registry allows for inclusion of previously under-represented cases of PSC.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Kuo A, Gomel R, Safer R, et al. Characteristics and Outcomes Reported by Patients With Primary Sclerosing Cholangitis Through an Online Registry. Clin Gastroenterol Hepatol. 2018. PMID: 29705262. doi:10.1016/j.cgh.2018.04.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。